Key facts
- This page summarizes Mary DiBiase's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 27 Jun 2022, 16:09.
Mary DiBiase - 24 Jun 2022 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- XFOR
- Reported as of
- 24 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Jun 2022, 16:09:20 UTC
- Prior SEC filing
- 17 Jun 2022
- Next SEC filing
- 01 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Derek M. Meisner, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mary DiBiase filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 27 Jun 2022.
Change
- Previous filing in this sequence was filed on 17 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
XFOR
transaction
Common Stock
Sale
- Transaction value
- Shares
- -856
- Change %
- -0.47%
- Price
- Shares after
- 181,187
- Date
- 24 Jun 2022
- Ownership
- Direct
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
Footnote F2
Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award
Footnote F3
The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.06 to $1.11, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Footnote F4
Of the shares of common stock reported, 171,916 shares represent unvested restricted stock units.